Abstract
Background: Mongolia started its nationwide vaccination campaign against COVID-19 on 23 February 2021 after receiving the first batch of the inactivated BBIBP-CorV. Age and body habitus of vaccinees may be associated with the immune effecter functions. Several systematic reviews and meta-analyses suggested lower immunogenicity of vaccines against SARS-CoV-2 infection in the older adult population and obese individuals. We aimed to establish a possible relationship between post-vaccine seroconversion rate and some biometric characteristics in the Mongolian cohort of vaccinees after two shots of the Sinopharm BBIBP-CorV vaccine. Materials and Methods: We collected serum samples from 846 eligible vaccinees before the first dose of the BBIBP-CorV vaccine and 21-28 days after the second dose of the same vaccine. Anti-SARS-CoV-2 Receptor Binding Domain (RBD) Immunoglobulin class G (IgG) and M (IgM) titer were measured in all samples. Results: 686 (81.1%) of 846 vaccinees received the Sinopharm BBIBP-CorV vaccine demonstrated seroconversion. Vaccinees with seroconversion had a younger mean age and lower mean body-mass index (BMI) than non-responders. Seroconversion rate according to age of vaccinees tends to decrease and obese vaccinees demonstrated a greater portion among non-responders. The Optimal Cut-Point (OCP) of age for seroconversion was found to differ significantly in male and female vaccinees. BMI has shown prediction ability for seroconversion only in male vaccinees but not in females. Using Receiver Operating Characteristics (ROC) analysis, we found 39 years for males and 41 years for females as a crucial milestone increasing the probability of seronegativity 2.5 times on average. A BMI higher than 29.1kg/m2 in male vaccinees was considered an acceptable predictor for seroconversion increasing the probability of seronegativity 2.4 times on average. Conclusion: The above findings allow us to summarize the sex-adjusted approach to biometric characteristics has an improved predictiveness for post-vaccine antibody response.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
